Bulletin
Investor Alert

New York Markets After Hours

Inovio Pharmaceuticals Inc.

NAS: INO

GO
/marketstate/country/us

After Hours

 --Real time quotes

Jul 28, 2021, 4:54 p.m.

INO
/zigman2/quotes/202993817/composite

$

8.73

Change

+0.06 +0.69%

Volume

Volume 9,640

Real time quotes

/zigman2/quotes/202993817/composite

Today's close

$ 8.26

$ 8.67

Change

+0.41 +4.96%

Day low

Day high

$8.27

$8.74

Open

52 week low

52 week high

$5.81

$22.93

Open

Company Description

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founde...

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Valuation

Price to Sales Ratio

185.24

Price to Book Ratio

3.59

Enterprise Value to Sales

134.97

Total Debt to Enterprise Value

0.04

Efficiency

Revenue/Employee

28,287.00

Income Per Employee

-635,157.00

Receivables Turnover

0.70

Total Asset Turnover

0.02

Liquidity

Current Ratio

11.30

Quick Ratio

11.30

Cash Ratio

9.87

Profitability

Operating Margin

-1,760.60

Pretax Margin

-2,197.89

Net Margin

-2,245.39

Return on Assets

-47.85

Return on Equity

-71.64

Return on Total Capital

-43.13

Return on Invested Capital

-55.59

Capital Structure

Total Debt to Total Equity

8.47

Total Debt to Total Capital

7.81

Total Debt to Total Assets

7.18

Long-Term Debt to Equity

7.96

Long-Term Debt to Total Capital

7.34

Officers and Executives

Name Age Officer Since Title
Dr. J. Joseph Kim 50 2009 President, Chief Executive Officer & Director
Dr. Jacqueline E. Shea 53 2019 Chief Operating Officer & Executive Vice President
Mr. Peter D. Kies 55 2002 Chief Financial & Accounting Officer
Dr. Kate E. Broderick - 2007 Senior Vice President-Research & Development
Dr. Mammen P. Mammen 55 2020 Senior Vice President-Clinical Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/09/2021 Peter D. Kies
CFO
33,750   Disposition at $10.01 per share. 337,837
06/09/2021 Laurent M. Humeau
Chief Scientific Officer
10,318   Disposition at $9.07 per share. 93,584
06/09/2021 Jacqueline E. Shea
Chief Operating Officer
38,535   Disposition at $10.01 per share. 385,735
06/09/2021 Peter D. Kies
CFO
13,750   Derivative/Non-derivative trans. at $2.16 per share. 29,700
06/03/2021 Peter D. Kies
CFO
10,000   Disposition at $8.03 per share. 80,300
05/17/2021 David B. Weiner
Director
3,045   Disposition at $6.62 per share. 20,157
05/17/2021 Simon X. Benito
Director
3,045   Disposition at $6.62 per share. 20,157
05/17/2021 Lota S. Zoth
Director
2,045   Disposition at $6.62 per share. 13,537
05/14/2021 David B. Weiner
Director
8,700   Derivative/Non-derivative trans. at $0 per share. 0
05/14/2021 Simon X. Benito
Director
8,700   Derivative/Non-derivative trans. at $0 per share. 0
05/14/2021 Wendy L. Yarno
Director
8,700   Derivative/Non-derivative trans. at $0 per share. 0
05/14/2021 Ann Calby Miller
Director
8,700   Derivative/Non-derivative trans. at $0 per share. 0
05/14/2021 Lota S. Zoth
Director
8,700   Derivative/Non-derivative trans. at $0 per share. 0
05/14/2021 Jay P. Shepard
Director
8,700   Derivative/Non-derivative trans. at $0 per share. 0
04/21/2021 David B. Weiner
Director
4,083   Disposition at $8.54 per share. 34,868
04/21/2021 David B. Weiner
Director
22,500   Disposition at $8.57 per share. 192,825
04/21/2021 Peter D. Kies
CFO
10,000   Disposition at $8.52 per share. 85,200
04/21/2021 David B. Weiner
Director
22,500   Derivative/Non-derivative trans. at $2.4 per share. 54,000
04/16/2021 Simon X. Benito
Director
2,000   Disposition at $8.75 per share. 17,500
04/16/2021 Simon X. Benito
Director
2,000   Derivative/Non-derivative trans. at $3.56 per share. 7,120
03/26/2021 Jacqueline E. Shea
Chief Operating Officer
4,710   Disposition at $8.97 per share. 42,248
03/25/2021 Jacqueline E. Shea
Chief Operating Officer
7,247   Derivative/Non-derivative trans. at $9.06 per share. 65,657
03/25/2021 Jacqueline E. Shea
Chief Operating Officer
16,667   Derivative/Non-derivative trans. at $0 per share. 0
03/21/2021 Ann Calby Miller
Director
4,274   Derivative/Non-derivative trans. at $0 per share. 0
03/16/2021 Simon X. Benito
Director
2,000   Disposition at $10.41 per share. 20,820
03/16/2021 Simon X. Benito
Director
2,000   Derivative/Non-derivative trans. at $3.56 per share. 7,120
/news/latest/company/us/ino

MarketWatch News on INO

  1. Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

    1 min ago

    - MarketWatch Automation

  2. Inovio Pharmaceuticals Inc. stock outperforms market on strong trading day

    5:00 p.m. July 26, 2021

    - MarketWatch Automation

  3. Inovio Pharmaceuticals Inc. stock falls Friday, underperforms market

    5:00 p.m. July 23, 2021

    - MarketWatch Automation

  4. Inovio Pharmaceuticals Inc. stock rises Wednesday, outperforms market

    5:00 p.m. July 21, 2021

    - MarketWatch Automation

  5. Inovio Pharmaceuticals Inc. stock rises Thursday, outperforms market

    5:00 p.m. July 15, 2021

    - MarketWatch Automation

  6. Inovio Pharmaceuticals Inc. stock falls Wednesday, underperforms market

    5:00 p.m. July 14, 2021

    - MarketWatch Automation

  7. Inovio Pharmaceuticals Inc. stock falls Monday, underperforms market

    5:00 p.m. July 12, 2021

    - MarketWatch Automation

  8. Inovio Pharmaceuticals Inc. stock outperforms market on strong trading day

    5:00 p.m. July 8, 2021

    - MarketWatch Automation

  9. Inovio Pharmaceuticals Inc. stock falls Wednesday, underperforms market

    5:00 p.m. July 7, 2021

    - MarketWatch Automation

  10. Inovio Pharmaceuticals Inc. stock falls Friday, underperforms market

    5:00 p.m. July 2, 2021

    - MarketWatch Automation

  11. Loading more headlines...
/news/nonmarketwatch/company/us/ino

Other News on INO

  1. Is Inovio Pharmaceuticals Primed For a Comeback?

    6:20 a.m. July 22, 2021

    - Motley Fool

  2. 5 Heavily Short-Sold Stocks That Won't Squeeze

    6:36 a.m. July 18, 2021

    - Motley Fool

  3. Bear of the Day: Inovio Pharmaceuticals (INO)

    10:05 a.m. July 12, 2021

    - Zacks.com

  4. Here's Why Inovio Pharmaceuticals Soared 23% In June

    2:14 p.m. July 8, 2021

    - Motley Fool

  5. 5 Ultra-Popular Stocks to Avoid Like the Plague in July

    6:06 a.m. July 5, 2021

    - Motley Fool

  6. Inovio Has 4 Sources Of Potential Value

    9:17 p.m. June 22, 2021

    - Seeking Alpha

  7. Inovio Pharmaceuticals Could See a Boost from Covid-19 Partnerships

    4:51 p.m. June 21, 2021

    - InvestorPlace.com

  8. Will coronavirus eventually become like the seasonal flu?

    9:19 a.m. June 20, 2021

    - Seeking Alpha

  9. Should You Buy Biotech ETFs Now?

    12:19 p.m. June 16, 2021

    - Zacks.com

  10. Why Inovio Stock Is Sinking Today

    11:46 a.m. June 10, 2021

    - Motley Fool

  11. Reddit favorite Inovio Pharmaceuticals takes a breather; down 9%

    11:27 a.m. June 10, 2021

    - Seeking Alpha

  12. Loading more headlines...

At a Glance

Inovio Pharmaceuticals, Inc.

660 West Germantown Pike

Suite 110

Plymouth Meeting, Pennsylvania 19462-1111

Phone

1 2674404200

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$7.41M

Net Income

$-166.41M

2020 Sales Growth

80.2%

Employees

262.00

/news/pressrelease/company/us/ino

Press Releases on INO

  1. Loading more headlines...
Link to MarketWatch's Slice.